Nonalcoholic Fatty Liver Disease: Role of Medical Colleges in its Prevention and Control
- PMID: 36034237
- PMCID: PMC9400341
- DOI: 10.4103/ijcm.ijcm_900_21
Nonalcoholic Fatty Liver Disease: Role of Medical Colleges in its Prevention and Control
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis.Am J Med. 2018 Dec;131(12):1515.e1-1515.e10. doi: 10.1016/j.amjmed.2018.07.011. Epub 2018 Aug 1. Am J Med. 2018. PMID: 30075104
-
Quality of life in patients with nonalcoholic fatty liver disease in combination with essential hypertension considering taste sensitivity to sodium chloride.Wiad Lek. 2016;69(2 Pt 2):204-7. Wiad Lek. 2016. PMID: 27487534
-
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.Ann Intern Med. 2005 Nov 15;143(10):722-8. doi: 10.7326/0003-4819-143-10-200511150-00009. Ann Intern Med. 2005. PMID: 16287793
-
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.Curr Opin Lipidol. 2008 Jun;19(3):295-300. doi: 10.1097/MOL.0b013e3282ff5e55. Curr Opin Lipidol. 2008. PMID: 18460922 Review.
-
Treatment of nonalcoholic fatty liver: present and emerging therapies.Semin Liver Dis. 2001;21(1):81-8. doi: 10.1055/s-2001-12931. Semin Liver Dis. 2001. PMID: 11296699 Review.
Cited by
-
Helicobacter pylori infection and association with chronic diseases: A focus on cardiovascular disease, MASLD, and type 2 diabetes.Metabol Open. 2025 Aug 11;27:100385. doi: 10.1016/j.metop.2025.100385. eCollection 2025 Sep. Metabol Open. 2025. PMID: 40893911 Free PMC article. Review.
-
Non-alcohlic Fatty Liver Disease (NAFLD): Is it a Dormant Volcano or Tip of an Iceberg?Indian J Community Med. 2024 Nov-Dec;49(6):780-785. doi: 10.4103/ijcm.ijcm_174_24. Epub 2024 Oct 17. Indian J Community Med. 2024. PMID: 39668912 Free PMC article.
References
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
-
- Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. - PubMed
-
- Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793–801. - PubMed
LinkOut - more resources
Full Text Sources